Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol

Cancer Letters

Volumn 328, Issue 2, 2013, Pages 285-296

  Gopalan, Archana ^a   Yu, Weiping ^b   Sanders, Bob G ^b   Kline, Kimberly ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Aldehyde dehydrogenase activity positive (ALDH+); Cancer stem like cells (CSCs); Cluster determinant (CD) positive negative (CD44+ CD24 ); Gamma tocotrienol ( T3); Signal transducer and activator of transcription 3 (Stat 3); Simvastatin (SVA)

Indexed keywords

CERAMIDE; GAMMA TOCOTRIENOL; MEVALONIC ACID; SIMVASTATIN; STAT3 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER STEM CELL; CONTROLLED STUDY; DRUG ELIMINATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CERAMIDES; CHROMANS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MEVALONIC ACID; NEOPLASTIC STEM CELLS; RETINAL DEHYDROGENASE; SIGNAL TRANSDUCTION; SIMVASTATIN; STAT3 TRANSCRIPTION FACTOR; VITAMIN E;

EID: 84870363768     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.003     Document Type: Article

References (68)

1. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608:1-22.
2. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62:233-247.
3. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
4. Moitra K., Lou H., Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 2011, 89:491-502.
5. Liu S., Wicha M.S. Targeting breast cancer stem cells. J. Clin. Oncol. 2010, 28:4006-4012.
6. Rasheed Z.A., Kowalski J., Smith B.D., Matsui W. Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells. 2011, 29:883-887.
7. Su F., Ren F., Rong Y., Wang Y., Geng Y., Wang Y., Feng M., Ju Y., Li Y., Zhao Z.J., Meng K., Chang Z. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 2012, 14:R38.
8. Aggarwal B.B., Sethi G., Ahn K.S., Sandur S.K., Pandey M.K., Kunnumakkara A.B., Sung B., Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci. 2006, 1091:151-169.
9. Lin L., Liu A., Peng Z., Lin H.J., Li P.K., Li C., Lin J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011, 71:7226-7237.
10. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., Margolick J.B., Liotta L.A., Petricoin E., Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 2007, 104:16158-16163.
11. Dulak J., Jozkowiez A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Targets 2005, 5:579-594.
12. Spampanato C., De M.S., Sarnataro M., Giordano E., Zanfardino M., Baiano S., Cartenì M., Morelli F. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int. J. Oncol. 2012, 40:935-941.
13. Cho S.J., Kim J.S., Kim J.M., Lee J.Y., Jung H.C., Song I.S. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 2008, 123:951-957.
14. Ghosh-Choudhury N., Mandal C.C., Ghosh-Choudhury N., Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell. Signal. 2010, 22:749-758.
15. Kochuparambil S.T., Al-Husein B., Goc A., Soliman S., Somanath P.R. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J. Pharmaco. Exp. Ther. 2011, 336:496-505.
16. Sassano A., Platanias L.C. Statins in tumor suppression. Cancer Lett. 2008, 260:11-19.
17. Campbell M.J., Esserman L.J., Zhou Y., Shoemaker M., Lobo M., Borman E., Baehner F., Kumar A.S., Adduci K., Marx C., Petricoin E.F., Liotta L.A., Winters M., Benz S. Breast cancer growth prevention by statins. Cancer Res. 2006, 66:8707-8714.
18. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metanalysis. Int. J. Cancer 2006, 120:833-843.
19. Garwood E.R., Kumar A.S., Baehner F.L., Moore D.H., Au A., Hylton N., Flowers C.I., Garber J., Lesnikoski B.A., Hwang E.S., Olopade O., Port E.R., Campbell M., Esserman L.J. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 2010, 119:137-144.
20. Chae Y.K., Garwood E.R., Valsecchi M.E., Kim J., Bianchi A.L., Khemasuwan D., Desai A., Tester W. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011, 29:585-593.
21. Ahern T.P., Chae Y.K., Garwood E.R., Pedersen L., Tarp M., Cronin-Fenton D.P., Garne J.P., Silliman R.A., Sørensen H.T., Lash T.L. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl. Cancer Inst. 2011, 103:1461-1468.
22. Gauthaman K., Manasi N., Bongso A. Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br. J. Pharmacol. 2009, 157:962-973.
23. Ju J., Picinich S.C., Yang Z., Zhao Y., Suh N., Kong A.N., Yang C.S. Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 2010, 31:533-542.
24. Kannappan R., Gupta S.C., Kim J.H., Aggarwal B.B. Tocotrienols fight cancer by targeting multiple cell signaling pathways. Genes Nutr. 2012, 7:43-52.
25. Aggarwal B.B., Sundaram C., Prasad S., Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem. Pharmacol. 2010, 80:1613-1631.
26. Luk S.U., Yap W.N., Chiu Y.T., Lee D.T., Ma S., Lee T.K., Vasireddy R.S., Wong Y.C., Ching P., Nelson C., Yap Y.L., Ling M.T. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 2011, 128:2182-2191.
27. Sylvester P.W., Wali V.B., Bachawal S.V., Shirode A.B., Ayoub N.M., Akl M.R. Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci. 2011, 17:3183-3195.
28. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63:1270-1279.
29. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant breast carcinoma cells. Int. J. Cancer 1994, 58:400-406.
30. Tiwary R., Yu W., deGraffenried L.A., Sanders B.G., Kline K. Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer. Breast Cancer Res. 2011, 13:R120.
31. Calcagno A.M., Salcido C.D., Gillet J.P., Wu C.P., Fostel J.M., Mumau M.D., Gottesman M.M., Varticovski L., Ambudkar S.V. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 2010, 102:1637-1652.
32. Calcagno A.M., Fostel J.M., To K.K., Salcido C.D., Martin S.E., Chewning K.J., Wu C.P., Varticovski L., Bates S.E., Caplen N.J., Ambudkar S.V. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br. J. Cancer 2008, 98:1515-1524.
33. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl Cancer Inst. 2006, 98:1777-1785.
34. Hellsten R., Johansson M., Dahlman A., Sterner O., Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS ONE 2011, 6:e22118.
35. Kotamraju S., Williams C.L., Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007, 67:7386-7394.
36. Jiang Q., Rao X., Kim C.Y., Freiser H., Zhang Q., Jiang Z., Li G. Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide. Int. J. Cancer 2012, 130:685-693.
37. Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 2004, 229:567-585.
38. Ahn K.S., Sethi G., Krishnan K., Aggarwal B.B. Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem. 2007, 282:809-820.
39. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
40. O'Brien C.S., Howell S.J., Farnie G., Clarke R.B. Resistance to endocrine therapy: are breast cancer stem cells the culprits?. J. Mammary Gland Biol. Neoplasia 2009, 14:45-54.
41. Lacerda L., Pusztai L., Woodward W.A. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Res. Update 2010, 13:99-108.
42. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., Barrow D., Nicholson R.I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer 2006, 118:290-301.
43. Cufi S., Corominas-Faja B., Vazquez-Martin A., Oliveras-Ferraros C., Dorca J., Bosch-Barrera J., Martin-Castillo B., Menendez J.A. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012, 3:395-398.
44. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
45. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
46. Croker A.K., Goodale D., Chu J., Postenka C., Hedley B.D., Hess D.A., Allan A.L. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 2009, 13:2236-2252.
47. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., Bornmann W., Bromberg J.F. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007, 9:R32.
48. - stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
49. Lin L., Liu Y., Li H., Li P.K., Fuchs J., Shibata H., Iwabuchi Y., Lin J. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Br. J. Cancer 2011, 105:212-220.
50. Vartanian R., Masri J., Martin J., Cloninger C., Holmes B., Artinian N., Funk A., Ruegg T., Gera J. AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/itch-mediated JUNB degradation. Mol. Cancer Res. 2011, 9:115-130.
51. Fishman P., Bar-Yehuda S., Ardon E., Rath-Wolfson L., Barrer F., Ochaion A., Madi L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 2003, 23:2077-2083.
52. Squarize C.H., Castilho R.M., Sriuranpong V., Pinto D.S., Gutkind J.S. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006, 8:733-746.
53. Page B.D., Ball D.P., Gunning P.T. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin. Ther. Pat. 2011, 21:65-83.
54. Weerasinghe P., Garcia G.E., Zhu Q., Yuan P., Feng L., Mao L., Jing N. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 2007, 31:129-136.
55. Lin L., Hutzen B., Zuo M., Ball S., Deangelis S., Foust E., Pandit B., Ihnat M.A., Shenoy S.S., Kulp S., Li P.K., Li C., Fuchs J., Lin J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010, 70:2445-2454.
56. Duan Z., Bradner J.E., Greenberg E., Levine R., Foster R., Mahoney J., Seiden M.V. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin. Cancer Res. 2006, 12:6844-6852.
57. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leeder J.S., Freedman M., Cohen A., Gazit A., Levitzki A., Roifman C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
58. Iwamaru A., Szymanski S., Iwado E., Aoki H., Yokoyama T., Fokt I., Hess K., Conrad C., Madden T., Sawaya R., Kondo S., Priebe W., Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007, 26:2435-2444.
59. Guzman M.L., Rossi R.M., Karnischky L., Li X., Peterson D.R., Howard D.S., Jordan C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
60. Montales M.T., Rahal O.M., Kang J., Rogers T.J., Prior R.L., Wu X., Simmen R.C. Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells. Carcinogenesis 2012, 33:652-660.
61. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., Yu Y., Clouthier S.G., Schwartz S.J., Wicha M.S., Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 2010, 16(9):2580-2590. (Epub 2010, April 13).
62. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., Liu S., Dontu G., Wicha M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 2010, 122:777-785.
63. Li Y., Wicha M.S., Schwartz S.J., Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J. Nutr. Biochem. 2011, 22:799-806.
64. Saydmohammed M., Joseph D., Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell. Biochem. 2010, 110:447-456.
65. Kannappan R., Yadav V.R., Aggarwal B.B. Γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem. 2010, 285:33520-33528.
66. Ginestier C., Monville F., Wicinski J., Cabaud O., Cervera N., Josselin E., Finetti P., Guille A., Larderet G., Viens P., Sebti S., Bertucci F., Birnbaum D., Charafe-Jauffret E. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012, 30:1327-1337.
67. Bonetti P.O., Lerman L.O., Napoil C., Lerman A. Statin effects beyond lipid lowering - are they clinically relevant?. Eur. Heart J. 2003, 24:225-248.
68. Yap S.P., Yuen K.H., Wong J.W. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 2001, 53:67-71.